Atrasentan for children with IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and under 18 years old.
- You must have been diagnosed with IgA nephropathy by a kidney biopsy within the last 3 years.
- Your kidney function must be at least 30 mL/min/1.73m², which is a measure of how well your kidneys filter waste.
- You must have a high level of protein in your urine (at least 1 gram per gram of creatinine) despite taking a stable dose of an ACE inhibitor or ARB (blood pressure medicines that also protect the kidneys) for at least 4 months.
- You must weigh at least 10 kg (22 pounds).
- Your parent or guardian must agree to the study and you must be able to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to atrasentan for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new medicine called BHV-1400 for adults with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if it's safe and effective in slowing the disease.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.